Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)
Main Article Content
Keywords
Deucravacitinib, psoriasis, tyrosine kinase 2, phase 3 clinical trial, efficacy, apremilast
References
1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736.
2. Wrobleski ST et al. J Med Chem. 2019;62:8973-8995.
3. SOTYKTUTM (deucravacitinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; September 2022.
4. Armstrong AW, et al. J Am Acad Dermatol. 2023;88:29-39.
5. Strober B, et al. J Am Acad Dermatol. 2023;88:40-51.
6. Warren RB, et al. Presented at the EADV 30th Congress; September 29-October 2, 2021.
2. Wrobleski ST et al. J Med Chem. 2019;62:8973-8995.
3. SOTYKTUTM (deucravacitinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; September 2022.
4. Armstrong AW, et al. J Am Acad Dermatol. 2023;88:29-39.
5. Strober B, et al. J Am Acad Dermatol. 2023;88:40-51.
6. Warren RB, et al. Presented at the EADV 30th Congress; September 29-October 2, 2021.